Abstract
Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising biomarkers for reliable detection of Alzheimer’s disease (AD) pathology. Various p-tau217 assays have been developed, but their relative performance is unclear. We compared key plasma p-tau217 tests using cross-sectional and longitudinal measures of amyloid-β (Aβ)-PET, tau-PET, and cognition as outcomes, and benchmarked them against cerebrospinal fluid (CSF) biomarker tests.
Samples from 998 individuals (mean[range] age 68.5[20.0-92.5], 53% female) from the Swedish BioFINDER-2 cohort were analyzed. Plasma p-tau217 was measured with mass spectrometry (MS) assays (the ratio between phosphorylated and non-phosphorylated [%p-tau217WashU]and p-tau217WashU) as well as with immunoassays (p-tau217Lilly, p-tau217Janssen, p-tau217ALZpath). CSF biomarkers included p-tau217Lilly, and the FDA-approved p-tau181/Aβ42Elecsys and p-tau181Elecsys.
All plasma p-tau217 tests exhibited high ability to detect abnormal Aβ-PET (AUC range: 0.91-0.96) and tau-PET (AUC range: 0.94-0.97). Plasma %p-tau217WashU had the highest performance, with significantly higher AUCs than all the immunoassays (Pdiff<0.007). For detecting Aβ-PET status, %p-tau217WashU had an accuracy of 0.93 (immunoassays: 0.83-0.88), sensitivity of 91% (immunoassays: 84-87%), and a specificity of 94% (immunoassays: 85-89%). Among immunoassays, p-tau217Lilly and plasma p-tau217ALZpath had higher AUCs than plasma p-tau217Janssen for Aβ-PET status (Pdiff<0.006), and p-tau217Lilly outperformed plasma p-tau217ALZpath for tau-PET status (Pdiff=0.025). Plasma %p-tau217WashU exhibited higher associations with all PET load outcomes compared to immunoassays; baseline Aβ-PET load (R2: 0.72; immunoassays: 0.47-0.58; Pdiff<0.001), baseline tau-PET load (R2: 0.51; immunoassays: 0.38-0.45; Pdiff<0.001), longitudinal Aβ-PET load (R2: 0.53; immunoassays: 0.31-0.38; Pdiff<0.001) and longitudinal tau-PET load (R2: 0.50; immunoassays: 0.35-0.43; Pdiff<0.014). Among immunoassays, plasma p-tau217Lilly was more strongly associated with Aβ-PET load than plasma p-tau217Janssen (Pdiff<0.020) and with tau-PET load than both plasma p-tau217Janssen and plasma p-tau217ALZpath (all Pdiff<0.010). Plasma %p-tau217 also correlated more strongly with baseline cognition (Mini-Mental State Examination[MMSE]) than all immunoassays (R2 %p-tau217WashU: 0.33; immunoassays: 0.27-0.30; Pdiff<0.024). The main results were replicated in an external cohort from Washington University in St Louis (n =219). Finally, p-tau217Nulisa showed similar performance to other immunoassays in subsets of both cohorts.
In summary, both MS-and immunoassay-based p-tau217 tests generally perform well in identifying Aβ-PET, tau-PET, and cognitive abnormalities, but %p-tau217WashU performed significantly better than all the examined immunoassays. Plasma %p-tau217 may be considered as a stand-alone confirmatory test for AD pathology, while some immunoassays might be better suited as triage tests where positive results are confirmed with a second test.
Competing Interest Statement
N.W G.S S.J N.M.C D.B A.O.D H.K A.A C.A.R T.L.S.B J.C.M L.I J.T N.J.A. B.A K.B and A.P.B report no competing interests. N.R.B is co-inventor on a US patent application Methods to detect novel tau species in CSF and use thereof to track tau neuropathology in Alzheimers disease and other tauopathies and CSF phosphorylated tau and Amyloid beta profiles as biomarkers of tauopathies. N.R.B is co-inventors on a non-provisional patent application Methods of Diagnosing and Treating Based on Site-Specific Tau Phosphorylation. NRB receives royalty income based on technology (blood plasma assay and methods of diagnosing AD with phosphorylation changes) licensed by Washington University to C2N Diagnostics. N.R.B. and R.J.B. are co-inventors on US patent applications: Methods to detect novel tau species in CSF and use thereof to track tau neuropathology in Alzheimers disease and other tauopathies and CSF phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies. G.T.B is an employee of Johnson and Johnson Innovative Medicine. S.E.S has received consultancy/speaker fees from Eisai; Eli Lilly; and Novo Nordisk. CC has received research support from: GSK and EISAI. CC is a member of the scientific advisory board of Circular Genomics and owns stocks. CC is a member of the scientific advisory board of Admit. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie; Acumen; Alector; Alzinova; ALZPath; Amylyx; Annexon; Apellis; Artery Therapeutics; AZTherapies; Cognito Therapeutics; CogRx; Denali; Eisai; LabCorp; Merry Life; Nervgen; Novo Nordisk; Optoceutics; Passage Bio; Pinteon Therapeutics; Prothena; Red Abbey Labs; reMYND; Roche; Samumed; Siemens Healthineers; Triplet Therapeutics; and Wave; has given lectures in symposia sponsored by Alzecure; Biogen; Cellectricon,; Fujirebio; Lilly; Novo Nordisk; and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS) which is a part of the GU Ventures Incubator Program (outside submitted work). N.R.B. and R.J.B. are co-inventors on a non-provisional patent application: Methods of diagnosing and treating based on site-specific tau phosphorylation. R.J.B. co-founded C2N Diagnostics. Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics, blood plasma assay and methods of diagnosing Alzheimers disease with phosphorylation changes) that is licensed by Washington University to C2N Diagnostics. R.J.B. receives income from C2N Diagnostics for serving on the scientific advisory board. R.J.B. has received research funding from Avid Radiopharmaceuticals; Janssen; Roche/Genentech; Eli Lilly; Eisai; Biogen; AbbVie; Bristol Myers Squibb and Novartis. O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen; C2N Diagnostics; Eli Lilly; Eisai; Fujirebio; GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from Alzpath; BioArctic; Biogen; Bristol Meyer Squibb; Eisai; Eli Lilly; Fujirebio, Merck; Novartis; Novo Nordisk; Roche; Sanofi and Siemens.
Clinical Protocols
https://clinicaltrials.gov/study/NCT03174938
Funding Statement
The study was supported by the National Institute of Aging (R01AG083740); European Research Council (ADG-101096455); Alzheimers Association (ZEN24-1069572; SG-23-1061717); GHR Foundation; Swedish Research Council (2022-00775; 2021-02219); ERA PerMed (ERAPERMED2021-184); Knut and Alice Wallenberg foundation (2022-0231); Strategic Research Area MultiPark (Multidisciplinary Research in Parkinsons disease) at Lund University; Swedish Alzheimer Foundation (AF-980907; AF-994229); Swedish Brain Foundation (FO2021-0293; FO2023-0163); Parkinson foundation of Sweden (1412/22); Cure Alzheimers fund; Ronstrom Family Foundation; WASP and DDLS Joint call for research projects (WASP/DDLS22-066); Konung Gustaf V och Drottning Victorias Frimurarestiftelse; Skane University Hospital Foundation (2020-O000028); Regionalt Forskningsstod (2022-1259) and Swedish federal government under the ALF agreement (2022-Projekt0080; 2022-Projekt0107). The Knight ADRC cohort was supported by National Institute on Aging grants P30AG066444; P01AG03991; and P01AG026276. G.S. received funding from the European Unions Horizon 2020 Research and Innovation Program under Marie Sklodowska-Curie action grant agreement number 101061836; an Alzheimers Association Research Fellowship (AARF-22-972612); the Alzheimerfonden (AF-980942); Greta och Johan Kocks research grants and travel grants from the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinsons Disease) at Lund University. S.E.S. has received funding from the National Institute on Aging (#R01AG070941). J.C.M has received funding from the National Institute on Aging (#P30AG066444; # P01AG003991; and # P01AG026276). N.R.B. received funding from the Alzheimers Association Research Fellowship (AARF-16-443265); the Coins for Alzheimers Research Trust; Knight ADRC Developmental Projects and the Tracy Family SILQ Center which supported the development of the plasma p-tau MS assay and data collection for this study. R.J.B. support was from the Tracy Family SILQ Center. Alamar/NULISAdata from WU was generated with support by grants from the National Institutes of Health (R01AG044546 (CC); P01AG003991(CC; JCM); RF1AG053303 (CC); RF1AG058501 (CC); U01AG058922 (CC); RF1AG074007 (YJS)); the Chan Zuckerberg Initiative (CZI); the Michael J. Fox Foundation (LI; CC); the Department of Defense (LI- W81XWH2010849); the Alzheimers Association Zenith Fellows Award (ZEN-22-848604; awarded to CC); and an Anonymous foundation. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders; the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/) and the Departments of Neurology and Psychiatry at Washington University School of Medicine. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018; and #2019-02397); the European Unions Horizon Europe research and innovation programme under grant agreement No 101053962; and Swedish State Support for Clinical Research (#ALFGBG-71320). The precursor of 18F-flutemetamol was sponsored by GE Healthcare. The precursor of 18F-RO948 was provided by Roche. The funding sources had no role in the design and conduct of the study; in the collection; analysis; interpretation of the data; or in the preparation; review; or approval of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Swedish Ethical Review Authority gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
